<SEC-DOCUMENT>0001144204-13-020627.txt : 20130408
<SEC-HEADER>0001144204-13-020627.hdr.sgml : 20130408
<ACCEPTANCE-DATETIME>20130408161130
ACCESSION NUMBER:		0001144204-13-020627
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130408
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130408
DATE AS OF CHANGE:		20130408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		13748535

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v340740_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Date of Report (Date of Earliest Event Reported):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">April 8, 2013</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt">STAAR Surgical
Company</FONT><BR>
<FONT STYLE="font-size: 10pt">__________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><U>Delaware</U></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><U>0-11634</U></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><U>95-3797439</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(State or other jurisdiction</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(Commission</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(I.R.S. Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><U>1911 Walker Ave, Monrovia, California</U></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><U>91016</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Registrant&rsquo;s telephone number, including area code:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">626-303-7902</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not Applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.3pt 0pt 4.5pt; text-align: justify">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;<FONT STYLE="font-family: Wingdings"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 2.02</B></FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Results of Operations and Financial Condition</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.75in">On April 8, 2013, STAAR Surgical
Company issued a News Release announcing its preliminary financial results for first quarter 2013. A copy of the News Release
is furnished as Exhibit 99.1 to this current report.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 8.01</B></FONT></TD>
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; width: 90%"><B>Other Events</B></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.75in">On March, 26, 2013, STAAR Surgical
Company (the &ldquo;Company&rdquo;) filed a proxy statement (the &ldquo;Proxy Statement&rdquo;) for its 2013 annual meeting of
stockholders (the &ldquo;Annual Meeting&rdquo;) to be held on May 13, 2013.&nbsp; The Proxy Statement included a proposal to approve
the amendment and restatement of the Company&rsquo;s 2003 Omnibus Equity Incentive Plan to increase the number of shares of common
stock available for issuance under that plan by 1,250,000 shares as well as additional revisions as described in Proposal No.
2 in the Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.75in">The Company hereby supplements
the information contained in its Proxy Statement by providing an evaluation of the weighted average of the contractual life
of outstanding options, warrants and rights. The table below summarizes the additional disclosure about the outstanding
options and shares of common stock that remain available for issuance under the Company&rsquo;s equity compensation plan as
of March 15, 2013 (the record date).</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: black; border-bottom: Black 1pt solid">Plan Category</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Securities <BR>to be Issued Upon <BR>Exercise of <BR>Outstanding Options, <BR>Warrants and Rights <BR>(a)(1)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average <BR>Exercise Price of Outstanding Options, Warrants and Rights ($) <BR>(b)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted
    Average <BR>Remaining <BR>Contractual Life <BR>of Outstanding <BR>Options, Warrants <BR>and Rights (years) <BR>(c)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Securities <BR>Remaining Available <BR>for Future Issuance <BR>under Equity <BR>Compensation Plans <BR>(excluding securities <BR>reflected in column (a)) <BR>(d)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 42%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left; text-indent: -0.35pt; padding-left: 0.35pt">Equity Compensation Plans Approved by Stockholders</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: right">3,957,613</TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">(2)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: right"></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left"></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: right">5.64</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: right">6.41</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: right">274,035</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(1)&#9;As of March 15, 2013,
the Company also had 309,500 shares of outstanding restricted stock which are not reflected in the table because they are treated
as issued and outstanding and will not have additional dilutive impact on the Company when the awards vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)&#9;Consists
of 3,831,613 option awards and 126,000 restricted stock unit awards</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial Statements and Exhibits</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 14%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 86%; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 7.5pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;99.1</FONT></TD>
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">News Release, dated April 8, 2013, announcing STAAR Surgical Company's preliminary financial results for first quarter 2013.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">STAAR Surgical Company&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">April 8, 2013</FONT></TD>
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">By:</FONT></TD>
    <TD STYLE="width: 78%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><U>/s/ Barry G. Caldwell</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Barry G. Caldwell</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v340740_ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 90px; width: 223px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STAAR SURGICAL PROVIDES PRELIMINARY FIRST
QUARTER REVENUE RESULTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Visian&reg; ICL&trade; Revenue Increase
Approximately 24%, a Record Quarterly High</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Total Revenue Increase Approximately
16% to $18 Million</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MONROVIA, CA, April 8, 2013 -- STAAR Surgical Company (NASDAQ:
STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today <FONT STYLE="color: black">announced
that first quarter revenue is expected to be approximately $18 million, which would represent approximately 16% growth. All revenue
comparisons are to the same period prior year results. </FONT>The effect of foreign currency exchange reduced total company revenue
by approximately $750,000 during the quarter. <FONT STYLE="color: black">Visian ICL revenue grew approximately 24%, exceeding the
$10 million level in quarterly revenue for the first time in the Company&rsquo;s history.</FONT> STAAR <FONT STYLE="color: black">is
reporting the preliminary results due to previously scheduled meetings with investors on April 11-12 and the upcoming American
Society of Cataract and Refractive Surgeons Annual Conference. Final results for the first quarter are expected to be released
on May 1, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Our year is off to a good start, despite currency exchange
and backorder challenges,&rdquo; said Barry G. Caldwell, President &amp; CEO. &ldquo;Visian ICL revenue grew in 10 of our 11 targeted
markets during the quarter allowing us to achieve a quarterly revenue record for the product line. In Europe, revenue increased
approximately 57%, reflecting the growing acceptance of our new ICL CentraFLOW&trade; technology as well as the impact of an expanded
sales team in the region. The CentraFLOW technology simplifies the ICL treatment by making it a one-step procedure, which is more
convenient and cost effective for both the patient and surgeon. We are encouraged by the market demand we are generating for this
high margin product while LASIK volume seems to be under pressure globally. We continue to expect regulatory approval for the CentraFLOW
technology in Korea and India later this year. Visian ICL revenue grew in the U.S. by approximately 12% in the first quarter, likely
due to our on-going marketing, social media, and promotional activities. This 12% first quarter growth in the U.S. follows 10%
year over year growth during the second half of 2012 in a market where LASIK procedures are clearly declining.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;IOL revenue during the first quarter of this year
remained relatively flat. However, without the negative impact of the foreign exchange rate in Japan, global IOL revenue
would have grown by approximately 10%. With the introduction of the KS-SP Preloaded Acrylic IOL we saw a 25% IOL unit
increase in Japan. Additionally, we did exit the quarter with approximately $900,000 in backorders of our Pre-Loaded Acrylic
IOLs in Europe. Finally, we continue to make progress towards the full implementation of our manufacturing consolidation from
Japan and Switzerland facilities to the U.S., remaining on target with our pre-established product and quality metrics. We look forward to updating investors on our progress as well as our 2013 metrics on May 1,&rdquo; Mr. Caldwell
concluded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>About STAAR Surgical</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">STAAR, which has been dedicated solely
to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery
systems therefor. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's
lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer&reg; Lens or &quot;ICL.&quot; A lens
used to replace the natural lens after cataract surgery is called an intraocular lens or &quot;IOL.&quot; Over 350,000 Visian ICLs
have been implanted to date; to learn more about the ICL go to: </FONT>www.visianinfo.com<FONT STYLE="color: black">. STAAR has
approximately 300 full time employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, it manufactures in
the following locations: Nidau, Switzerland; Ichikawa City, Japan; Aliso Viejo, CA; and Monrovia, CA. For more information, please
visit the Company's website at </FONT>www.staar.com<FONT STYLE="font-size: 10pt; color: black">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Safe Harbor</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All statements in this press release that are not statements
of historical fact are forward-looking statements, including statements about any of the following: any projections or estimates
of earnings, revenue, sales, profit margins, cash or any other financial items; the plans, strategies, and objectives of management
for future operations or prospects for achieving such plans; metrics for 2013; statements regarding new products, including but
not limited to, expectations for success of the new ICL, KS-SP and nanoFLEX Toric IOL products in the U.S. or international markets
or government approval of new products; future economic conditions or size of market opportunities; expected savings from business
consolidation plans and the timetable for those plans; statements of belief; and any statements of assumptions underlying any of
the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These statements are based on expectations and assumptions
as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to
differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: our
limited capital resources and limited access to financing; the negative effect of unstable global economic conditions on sales
of products, especially products such as the ICL used in non-reimbursed elective procedures; the challenge of managing our foreign
subsidiaries; backlog as we prepare for our manufacturing facility consolidation; the risk of unfavorable changes in currency
exchange rate; the discretion of regulatory agencies to approve or reject new products, or to require additional actions before
approval; unexpected costs or delays that could reduce or eliminate the expected benefits of our consolidation plans; the risk
that research and development efforts will not be successful or may be delayed in delivering for launch; the purchasing patterns
of our distributors carrying inventory in the market; the willingness of surgeons and patients to adopt a new product and procedure;
patterns of Visian ICL use that have typically limited our penetration of the refractive surgery market, and a general decline
in the demand for refractive surgery particularly in the U.S. and the Asia Pacific region, which STAAR believes has resulted from
both concerns about the safety and effectiveness of laser procedures and current economic conditions. The Visian Toric ICL and
the Visian ICL with CentraFLOW are not yet approved for sale in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; padding-right: 5.4pt">CONTACT:</TD>
    <TD STYLE="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt">Investors</TD>
    <TD STYLE="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt">Media</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">EVC Group</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">EVC Group</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: -0.5in; padding-left: 5.4pt">Douglas Sherk, 415-652-9100</TD>
    <TD STYLE="padding-right: -0.5in; padding-left: 5.4pt">Amy Phillips, 412-327-9499 </TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: -0.5in; padding-left: 5.4pt">Leigh Salvo, 415-568-9348</TD>
    <TD STYLE="padding-right: -0.5in; padding-left: 5.4pt">&nbsp;</TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!:`-\#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W2X:ZM_WD
M0\Y.Z$?,/ICK_GK4":W:[`\Y,*$X$C<QY]-PX'T.#6E6?>Z9YSM/:RFWN2.6
M`RL@]'7H1[]:EWZ#5B\DB2H'C=74]&4Y!IU<<([9+S[/,9-%U`G(>%L0R]L@
M=,>W%69KKQ/I0S)!%J,`_CC&'_(?X&ESCY3J**Y2#QY8EMEW;3V[]#T8#^1_
M2M6#Q-HUP`4OXE_W\I_.FIQ?47*S6JM83BYLUE!R"SC\F(_I3'U6Q6WDF6[@
M=40L=L@/09K)\+WL4>C>5<S1QO'(<AV`X;Y\\_[U%]0MH=%16=+K^DPYWZA;
M\?W7#?RK+N?'&D0\1&:<]MB8'ZXH<HKJ'*SI:*Y.'Q#K>K?\@S2UBB/_`"VF
M)(QZYX'\Z9>QBW(76]2GO;A^%LK;Y0V>Q`_GQ^-+G70?*=%+JUG'*84E\Z8=
M8X1O(^N.!^.*C@O+B^.8$6.+O(3NS].Q_#(]ZJ6&DR31*U[%';V_5;&'A1[N
M1]X_I6V`%````'``IJ[W$[(%&U0"2?<TM%%4(****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`*FH:;:ZI:F"ZC#+U![J?4'M7)-?:IX/N5@N=UWIK'$;GJH
M]`>Q]J[BH;JUAO;9[>XC$D3C!4U,HWU6Y2?<S5BT7Q-:^=Y44X/!.,.OL2.1
M6'??#Z!R6L;IHS_<E&1^8Z?D:Q-3T^_\(ZHMQ:2OY#']V_8C^ZPKLO#_`(FM
M]:C$;8BNP/FCSPWNO^%9IQD[26I6JU6QQ4W@W6K>55$(E3/WHWR/RZ_I6CX@
M\,:C<ZVQL8"T3(GS;@`,*%[_`$KT&BG[*(N=G`V7P^F8AKZ[1!_=B&X_F>GZ
MUT=IX<T72(C,84.P9:6<YQ[\\"K^IZI:Z3:&XNI-J_PJ.K'T`KSJ^U;4_%>H
MK:0*5B8_)"IX'NQI/EALM1KFD;]_XIN=1NQIN@1EG)P9R.WJ/0>YK9T3P_#I
M0,\KFXO7^_,_/X#/\^]2:%H5OHEF(XP&F8?O)<<L?\*U:N,7O(EOH@HHK%L+
MZ;7);N2"<P6<$[6ZF,`O(R_>8DYP,\`=>,YYQ6B5]2+FU17/ZT^KZ5:K<V%R
MMQ$)$6:.XC!94+`%E*XZ9Z'-+KUQK7]JZ78Z1)#$)Q*UQ++%O"(NWG&1S\V,
M52A?J%S?HKC/&^LZMX7T&"]MKQ9IFG6)O,A7!!5CGCZ"M4QZU=Z'!<V6I1I=
MR0K(%E@4H6*@XXY`]^:.31.^XN;6QO45E>&[V[U#P_:7-^H6[<,)5"[<,&((
MQ^%87COQ9<>&FTW[,I*O<*UR0N1Y?/R\]"V#C_=-"@W+E6XW))7.RHID4J3P
MI-$P>.10RL.A!Y!I]0,**XWQKXNF\.7VE)"I,#3@W;;<@)TV_4\G_@-=BCK(
MBNC!E89!'0BJ<&DF^HDTW86BJ>H^>EI+-!<&(QQLV-H()`SWKEO`NN:IXJT>
MZNKN[$4D<YB7R8EQC:#SD'UIJ#<7(+ZV.UHKC(/%=[IOC1?#>KB*99P&MKJ)
M=A.>@9<D=01D?_JV[EM5_M0B$'[/MXP!C/\`G]:'!K<%*YL4445`PHHJ.5Y%
M&(H]['U.`/K0!6U6"SN--FCOBJVY7EF_A]"/>O-[&QLK"\^TWU^T4<;YC2+/
MFOCIQ_#^//\`.O09-%2]E$NI3/<E3E8@=D:?0#D_4DUC>,-`@?1A<6=O'$]M
MR5C4#*GKT].OYUE.+>MBXNVAOZ3JL&L67VJW#!-Q4ANH(_R*N.ZQQM(YPJ@D
MGT`KA_AY=?\`'Y:$^DBC]#_,5T/BJZ^R>'+MA]YU\L?B<'],U497CS":UL<E
MKEWIOB1A-!=O;W2#`AN>$8>QY`_&M_P98V=I8N48->M_KLC!4=@/;W[USG@G
M1UO]1>ZG0-#;C@,,AF/3^I_*NVDT"Q,HGMD:TG7[LEN=N/PZ?I6<$W[Q4FE[
MIJ457@-U'A+C;)Z2H,9^J]OP_2K%;F85YO=:)XM\*ZK>7?AQH[W3[F4S-:R8
MRI)YXR/ID')[UZ-(2(G*G!`.#63X8UZ#Q#H5O>Q2*92H6=!U1\<@CMZCVK2$
MG%-VNB9),Y*W^*/V2=;;Q%HES8.>"X4D?7:0#CZ9KT"WGANX([F!UDBD4,CK
MR"IYK$\:P64_A._2]C5\QD0`C+&4CY`O?.<=*F\):;/I'A33K&YSY\<67!/W
M226Q^&<?A53Y''F2L)73LSFOB]_R*5O_`-?J?^@O79:/_P`@2P_Z]H__`$$5
MQOQ>_P"12M_^OU/_`$%Z[+1_^0)8?]>T?_H(HE_"CZL%\;+A*HI)PJCDFN.U
MFRL_$7A74$>XMQ<W?[^$-(H*E?\`5CKQP.?]XUTFIYFCCLE/-RVUL=HQRY_+
MCZL*N!$`P%4?A41?+J4U?0XGX7:W_:?AG[#*V;BP;RSGJ4/W3_,?A7;.ZQQM
M([!44$L3V`KR^7_BC/BNLOW-.U8<^@+'G\GP?8&O0]2S.8;$?\O#9D_ZYKRW
MY\+_`,"JZL5S<RV>I,7I;L<OXAL;37_!MZKW$'VR<_:XE,BY5@/E7Z[1M^I-
M2?#/6_[6\*QV\KYN+$^0_KM_@/Y<?\!KL=B_W1^5>7VW_%&?%=X#\FGZM]WT
M!8\?DV1]#51?/!Q^:$]&F>DZC_R#+O\`ZXO_`.@FO//A++<1^';[R;;S1]K/
M/F!>=B\5Z'J'_(,N_P#KB_\`(UPGP>_Y%N^_Z_#_`.@+2A_"E\AOXD206UI=
M?$A;S793;:FJ#[%9D?(5&<,).C'.>..?I7H%>9_%%6M=9\.:D/E2*<AI/[I#
M*P_K^5>F`@C(.0:576,9!'=H****Q+"BBB@`ILD:2Q/'(H9'!5@>X-.HH`\Z
M\-Q-I/C:2R8]=\>3W&,@_C@5K?$"?;IEK;@\R2EL>N!C_P!FIFO0"S\::5>J
M,"=U1C[@@']"*/%4']H^)-)L#R#\S#_9)Y_1:PM:+B:;M,VO"^GC3M!MT*XD
MD'FO]3_];`K8H`P,#I16R5E8S;N%%%%,`(!!!&0:H_V/IRLKQV<,3J-H:)?+
M./3*XXJ\1D8J$1Q%B`[DCJ/,/^-%VM@&1Z?:QS+,(0TJ_==R79?H3G%6:B,*
M`9+.!_UT;_&D\J/CYWYZ?O#_`(T78%>YT;3+W/VJQMYP6W$2H&&?7!J>WLK:
MTXMX4B&,848XIQA0#)9\?]=&_P`:!%&V<.YQZ2'_`!IW>P61"^EV+RF1K6,R
M'/S$<\]:M`!5"@8`&`*9Y">LG_?QO\:;Y<6[;YC;AV\TY_G2NP*D^@Z3=$&Y
MTVUF*_=,L8;'TSTJ3^R=/W;OLD6[&,XYQ5GR$]9/^_C?XT@BC/1G/TD;_&GS
M,+(EQQCM6=-H&D7#*T^FVLK+]TR1ABOTSTJX8HU!+,X`[F1O\:!%&PRK.1ZB
M1O\`&DFUL%B`Z58,"#:QD'@@CK3+;1-+L\?9;"W@^;=B*,*,^O%6_(3^])_W
M\;_&CR$]9/\`OXW^-/F860R[L[:_MS!=V\4\)ZI*@8?D:2TL;:QC\NVA6)<`
M87T'0?2GF*,=6<?]M&_QIZ($S@M^+$_SI7>P#J***`"BBB@`HHHH`Y_Q;"#I
M]O==#;7"/GV)Q_/%`A^T>.6F/(MK0`>Q)_P)J_KL`N="O8R,_NF8#W'(_E46
MEIOU/4KKJ',2#\(P?_9JAKWBD]#6HHHJR0HHHH`.U<]IVR&_M8X]ES#('>*4
M`B6+/)#^HYQSWKH:*35QIE;48VFTRZB1=S/"X5?4X.*S[-H9K+28TVM)&%++
MCE,(0<^G/%;-%%M0N-?;Y;;L;<<YZ8KEM#0QMI37"^4H@*QO&/\`6,1RLA]1
MU'K75T4-78)D%X)C8W`MO]?Y;>7_`+V./UK%C:U32K$1P1R7`DB#I(#YBOD9
M8]\@Y)KH:*&K@F';FLO0@HLI=H`_TF7IZ;SC],5J446U$9%]@:Y:O=8^Q")@
MFX?*)<CD]NF<9J_:QVR^:UL%`=\ML'!;`&?3L*L446'<H:D3,JV*J6,X.\!L
M'8.O/OP/Q--T:XEDLS!<9^T6S&*0G^+'1OQ&/QS6C11;6X7,K6-@N=,9]N%N
MLDGL-C?UQ6A#<17!<1.'"'!(Z9^M2T46U`****8@HHHH`****`&R()(V1NC`
M@U4TN(Q6AR.6;)_``?TJ[34X7\3_`#I`.HHHI@%%%%`!1110`4444`%%%%`!
61110`4444`%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
